GRI Bio reiterates FY2025 results: $8.2M cash, $12M loss; raises $6.5M, runway into Q1 2027

GRI Bio, Inc.

2025-FY EPS reported -$121.80 vs consensus -$29.55 ▼ miss (-312.1%)

Cash and cash equivalents of $8.2M at Dec 31, 2025; raised additional $6.5M in Jan 2026 via ATM offering.
Net loss for FY2025 was $12M; R&D expenses increased to $6.8M from $3.8M year-over-year.
Cash runway expected to fund planned operations into the first quarter of 2027.
Positive Phase 2a data for GRI-0621 in idiopathic pulmonary fibrosis reinforces clinical proof-of-concept.
Advancing GRI-0803 for autoimmune indications through IND-enabling studies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.